Library.

“Anktiva (nogapendekin alfa inbakicept) is approved and clinically effective for treating, curing, or preventing all types of cancer, not solely bladder cancer.”

Anktiva (nogapendekin alfa inbakicept) is approved only for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, as confirmed by the FDA, EMA, and all major clinical references. It is not approved for any other cancer type. While early-phase trials have explored its use in other malignancies, no regulatory body has recognized it as effective for treating, curing, or preventing "all types of cancer." The claim dramatically overstates both the drug's approved scope and its demonstrated efficacy.

“ImmunityBio's drug N-803 (anktiva) is being investigated or has demonstrated efficacy in treating, curing, or preventing cancer types beyond bladder cancer.”

ImmunityBio's N-803 (Anktiva) is actively being investigated in multiple cancer types beyond bladder cancer, including pancreatic cancer, non-small cell lung cancer, glioblastoma, and other advanced solid tumors, as confirmed by ClinicalTrials.gov registrations and NCI-sponsored trials. Preliminary efficacy signals in NSCLC have been reported, though definitive Phase 3 proof of efficacy beyond bladder cancer has not yet been established. The claim's "being investigated" component is firmly supported by high-authority sources.